![hrd genes hrd genes](https://pbs.twimg.com/media/EYpjqOaWoAIELhc.jpg)
![hrd genes hrd genes](https://m.media-amazon.com/images/I/81XiogF2nAL._AC_US800_.jpg)
However, the currently available HRD assays are not perfect predictors of the clinical response to PARPis in EOC patients. Identification of BRCA mutations and/or homologous recombination deficiency (HRD) is critical for selecting patients for PARPi treatment. In recent years, promising survival benefits from maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) has changed the management of EOC in newly diagnosed and recurrent disease. 5Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, TaiwanĮpithelial ovarian cancer (EOC) patients are generally diagnosed at an advanced stage, usually relapse after initial treatments, which include debulking surgery and adjuvant platinum-based chemotherapy, and eventually have poor 5-year survival of less than 50%.4Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.3Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.2Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.1Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.Ying-Cheng Chiang 1, Po-Han Lin 2,3 and Wen-Fang Cheng 1,4,5*